Bone Biologics Files 8-K: Regulation FD & Exhibits
Ticker: BBLGW · Form: 8-K · Filed: Jun 20, 2024 · CIK: 1419554
| Field | Detail |
|---|---|
| Company | Bone Biologics Corp (BBLGW) |
| Form Type | 8-K |
| Filed Date | Jun 20, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, financial-reporting
Related Tickers: BBLG
TL;DR
BBLG filed an 8-K for Reg FD and exhibits, standard compliance.
AI Summary
On June 20, 2024, Bone Biologics Corporation filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and the filing of Financial Statements and Exhibits. No specific financial transactions or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates Bone Biologics Corporation is complying with regulatory disclosure requirements and submitting necessary financial documents to the SEC.
Risk Assessment
Risk Level: low — The filing is a routine disclosure and does not appear to contain any new material adverse information.
Key Numbers
- 001-40899 — SEC File Number (Identifies the specific SEC filing for Bone Biologics Corporation.)
Key Players & Entities
- Bone Biologics Corporation (company) — Registrant
- June 20, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 42-1743430 (tax_id) — IRS Number
FAQ
What specific items are being disclosed under Regulation FD?
The provided excerpt does not detail the specific content of the Regulation FD disclosure, only that it is being filed.
What financial statements and exhibits are being filed?
The excerpt states that Financial Statements and Exhibits are being filed, but does not list their specific contents.
What is the primary business of Bone Biologics Corporation?
Bone Biologics Corporation is in the business of Orthopedic, Prosthetic & Surgical Appliances & Supplies, as indicated by its SIC code 3842.
When was Bone Biologics Corporation incorporated?
The company was incorporated in Delaware, as stated in the filing.
Are there any significant changes or events reported in this 8-K?
The excerpt indicates the filing is for 'Regulation FD Disclosure' and 'Financial Statements and Exhibits', suggesting routine compliance rather than a specific material event.
Filing Stats: 516 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-06-20 08:05:27
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share BBLG Nasdaq Capital Mark
Filing Documents
- form8-k.htm (8-K) — 48KB
- ex99-1.htm (EX-99.1) — 17KB
- ex99-1_001.jpg (GRAPHIC) — 10KB
- 0001493152-24-024426.txt ( ) — 296KB
- bblg-20240620.xsd (EX-101.SCH) — 4KB
- bblg-20240620_def.xml (EX-101.DEF) — 26KB
- bblg-20240620_lab.xml (EX-101.LAB) — 36KB
- bblg-20240620_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BONE BIOLOGICS CORPORATION Date: June 20, 2024 By: /s/ Jeffrey Frelick Jeffrey Frelick Chief Executive Officer